In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards Lifesciences Corp.

www.edwards.com

Latest From Edwards Lifesciences Corp.

Market Brief: PBV Systems Fastest-Growing Segment In Global Surgical Heart Valve Management Market

The worldwide market for surgical heart valve products is expected to stay relatively flat, reaching $2bn in sales by 2023. The heart valve repair and replacement segments are expected to see small losses while the much smaller PBV systems market will grow at a CAGR of 12.7% by 2023, benefiting from a trend toward minimally invasive procedures.

Innovation Market Intelligence

Boston Scientific Becomes Third US TAVR Competitor With Lotus Edge Approval

The US FDA approved Boston Scientific's Lotus Edge transcatheter aortic valve for patients who would be at high risk with surgical valve replacement. Unlike competing TAVR systems from Medtronic and Edwards, Lotus Edge can be repositioned or recaptured after it has been deployed.

Approvals Innovation

Edwards’ Pascal Improves Mitral Regurgitation In Early Trial Results

One-month results from the CLASP trial, presented at the German Cardiology Meeting (DGK), show Edwards’ Pascal mitral valve repair device reduces mitral regurgitation in heart failure patients with moderate to severe mitral regurgitation.

Research & Development Clinical Trials

CMS Proposes More Flexible Requirements For Centers Performing TAVR

A proposed update to the 2012 National Coverage Policy for transcatheter aortic valve replacement (TAVR) would make it easier for hospitals to begin a TAVR program while slightly raising the procedure-volume requirements for maintaining a continuing TAVR program. The agency believes the new rules would balance the need to expand patient access to TAVR while ensuring the quality and safety of TAVR procedures covered by Medicare.

Medicare Policy & Regulation
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register